

Special Issue

The Evolving Role of CDK4/6 Inhibitors in Early and Recurrent Breast Cancer: Clinical and Translational Findings and Work in Progress

Message from the Guest Editor

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have fundamentally transformed the therapeutic landscape for hormone receptor-positive, HER2-negative breast cancer, establishing a new standard of care in both advanced and high-risk early-stage disease when combined with endocrine therapy. The clinical success of agents such as palbociclib, ribociclib, and abemaciclib is underpinned by their ability to arrest cell cycle progression at the G1/S checkpoint, resulting in significant improvements in progression-free and overall survival for select patient populations. Ongoing translational and clinical research is focused on elucidating mechanisms of resistance, refining patient selection, and exploring novel therapeutic combinations to maximize clinical benefit. This Special Issue aims to provide a comprehensive overview of the current state of clinical and translational CDK4/6 inhibitor research in both the early and metastatic settings, highlight recent mechanistic insights, and discuss future directions for clinical application and drug development in oncology.

Guest Editor

Prof. Dr. Hans-Christian Kolberg

Department of Gynecology and Obstetrics, Knappschaft Kliniken Marienhospital Bottrop, Josef-Albers-Straße 70, 46236 Bottrop, Germany

Deadline for manuscript submissions

31 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/261680

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)